Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI)

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 14, 2008, Pages 4224-4227

  Wu, Dongpei ^a   Pontillo, Joseph ^a   Ching, Brett ^a   Hudson, Sarah ^a   Gao, Yinghong ^a   Fleck, Beth A ^a   Gogas, Kathleen ^a   Wade, Warren S ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

Norepinephrine; Serotonin

Indexed keywords

ATOMOXETINE; DESIPRAMINE; DULOXETINE; FLUOXETINE; NBI 80532; NISOXETINE; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE;

ARTICLE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

ADRENERGIC UPTAKE INHIBITORS; AMINES; BINDING SITES; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DESIPRAMINE; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; MOLECULAR CONFORMATION; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PROPYLAMINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 47149097253     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.05.057     Document Type: Article

References (20)

1. Jann M.W., and Slade J.H. Pharmacotherapy 27 (2007) 1571
2. Babu R.P.K., and Maiti S.N. Heterocycles 69 (2006) 539
3. Zhou J. Drugs of the Future 29 (2004) 1235
4. Wernicke J.F., Iyengar S., and Ferrer-Garcia M.D. Curr. Drug Ther. 2 (2007) 161
5. Walter M.W. Drug Dev. Res. 65 (2005) 97
6. Iversen L. Mol. Psychiatry 5 (2000) 357
7. Mackay, M. Pfizer R&D Analyst Meeting 2006, Neurosciences slide 9, http://www.pfizer.com/investors/presentations/presentations.jsp, web site accessed 5/2008.
8. Maxwell R.A., and White H.L. Handbook Psychopharmacol. 14 (1978) 83
9. Wise R.A. Curr. Opin. Neurobiol. 6 (1996) 243
10. Boot J., Cases M., Clark B.P., Findlay J., Gallagher P.T., Hayhurst L., Man T., Montalbetti C., Rathmell R.E., Rudyk H., Walter M.W., Whatton M., and Wood V. Bioorg. Med. Chem. Lett. 15 (2005) 699
11. Reynolds C.H., Tounge B.A., and Bembenek S.D. J. Med. Chem. 51 (2008) 2432
12. Sauer J.-M., Ring Barbara J., and Witcher Jennifer W. Clin. Pharmacokinet. 44 (2005) 571
13. Bymaster F.P., Lee T.C., Knadler M.P., Detke M.J., and Iyengar S. Curr. Pharm. Des. 11 (2005) 1475
14. Kinbara K., Katsumata Y., and Saigo K. Chem. Lett. 31 (2002) 266
15. Compound 9c was crystalline and easily separated from the trans oil 9t by crystallization.
16. Tsunoda T., Otsuka J., Yamamiya Y., and Ito S. Chem. Lett. 23 (1994) 539
17. Kiankarimi, M.; Hudson, S.; Dwight, W. J.; Wade, W. S. Preparation of benzofuranylmethylamines, chromanylmethylamines, and thiochromanylmethylamines as monoamine reuptake inhibitors. US 2006252818.
18. 3-d) δ ppm 9.84 (s, 1H), 9.67 (s, 1H), 7.30 (t, J = 7 Hz, 1H), 7.20 (m, 3H), 7.16 (d, J = 7 Hz, 1H), 7.15 (t, J = 7 Hz, 1H), 7.04 (d, J = 8 Hz, 1H), 6.94 (t, J = 7 Hz, 1H), 5.45 (s, 1H), 3.77 (s, 1H), 3.40 (dd, J = 15, 4 Hz, 1H), 3.05 (dd, J = 15, 12 Hz, 1H), 2.72 (s, 3H) 2.14 (t, J = 12 Hz, 1H), 2.04 (s, 3H); APCI MS m/z 268.0.
19. Molecule structures were imported into the Molecular Operating Environment (MOE) software version 2007.09 and subjected to Stochastic Conformation Search using the MMFF94x force field with GBSA implicit solvation. Low-energy conformations within 1.5 kcal/mol from the minimum that were most consistent with the known solid-state X-ray crystal structures were taken forward and aligned using the Flexible Alignment module using default field similarity terms except hydrogen-bonding terms were scaled down to 0.5. The best scoring alignment most consistent with known structure-activity patterns for NET:SERT selectivity was retained.
20. Fuller R.W., Wong D.T., and Robertson D.W. Med. Res. Rev. 11 (1991) 17